Shi, C.; Kwong, D.L.-W.; Li, X.; Wang, X.; Fang, X.; Sun, L.; Tang, Y.; Guan, X.-Y.; Li, S.-S.
MAEL Augments Cancer Stemness Properties and Resistance to Sorafenib in Hepatocellular Carcinoma through the PTGS2/AKT/STAT3 Axis. Cancers 2022, 14, 2880.
https://doi.org/10.3390/cancers14122880
AMA Style
Shi C, Kwong DL-W, Li X, Wang X, Fang X, Sun L, Tang Y, Guan X-Y, Li S-S.
MAEL Augments Cancer Stemness Properties and Resistance to Sorafenib in Hepatocellular Carcinoma through the PTGS2/AKT/STAT3 Axis. Cancers. 2022; 14(12):2880.
https://doi.org/10.3390/cancers14122880
Chicago/Turabian Style
Shi, Chaoran, Dora Lai-Wan Kwong, Xue Li, Xia Wang, Xiaona Fang, Liangzhan Sun, Ying Tang, Xin-Yuan Guan, and Shan-Shan Li.
2022. "MAEL Augments Cancer Stemness Properties and Resistance to Sorafenib in Hepatocellular Carcinoma through the PTGS2/AKT/STAT3 Axis" Cancers 14, no. 12: 2880.
https://doi.org/10.3390/cancers14122880
APA Style
Shi, C., Kwong, D. L.-W., Li, X., Wang, X., Fang, X., Sun, L., Tang, Y., Guan, X.-Y., & Li, S.-S.
(2022). MAEL Augments Cancer Stemness Properties and Resistance to Sorafenib in Hepatocellular Carcinoma through the PTGS2/AKT/STAT3 Axis. Cancers, 14(12), 2880.
https://doi.org/10.3390/cancers14122880